Meritage Homes Extends Partnership with Operation Homefront, Donating Two Mortgage-Free Homes to Military Families in Colorado and North Carolina
The homebuilder's 12th year partnering with Operation Homefront's Permanent Homes for Veterans program
SCOTTSDALE, Ariz., May 20, 2025 (GLOBE NEWSWIRE) -- Meritage Homes has extended its partnership with Operation Homefront's Permanent Homes for Veterans Program to donate two brand new, mortgage-free homes for veteran families in Colorado Springs, Colorado and Raleigh, North Carolina. This marks the Company's 12th year partnering with the organization and 22 total donations to date.
'We are honored to deliver new homes to deserving military families who have given so much to our country. It's a privilege for us to help them achieve a fresh start to a new future and build roots in their communities,' shares Phillippe Lord, CEO of Meritage Homes. 'Thank you to our employees and trade partners for their time and effort. We're proud to continue our long-standing partnership with Operation Homefront and look forward to welcoming this year's recipients into their new, mortgage-free Meritage homes.'
The new homes will be in the Lorson Ranch community located in Colorado Springs, CO and in the River Glen community in Angier, NC. Both homes offer an open-concept floorplan with designer-curated interiors and energy-efficient features, including ENERGY STAR® appliances, a multispeed HVAC system, and spray-foam insulation. Each house is also outfitted with a smart home suite that gives homeowners the ability to set the thermostat, control security devices and more through a convenient app.
This year's recipients will be announced in September and presented the keys at ceremonies in November around Veterans Day.
'We are grateful for Meritage Homes' unwavering commitment to our mission to build strong, stable and secure military families,' said Rear Adm. Alan Reyes, US Navy (Ret.), Operation Homefront President & CEO. 'Each family receives more than a house, they are being given a place to call home, where they can gather to establish new traditions, create beautiful memories and realize life-changing dreams with generational impact.'
For more information about the Meritage's partnership with Operation Homefront, please visit: https://www.meritagehomes.com/operation-homefront.
About Meritage Homes Corporation: Meritage is the fifth-largest public homebuilder in the United States, based on homes closed in 2024. The Company offers energy-efficient and affordable entry-level and first move-up homes. Operations span across Arizona, California, Colorado, Utah, Tennessee, Texas, Alabama, Florida, Georgia, Mississippi, North Carolina, and South Carolina.
Meritage has delivered almost 200,000 homes in its 40-year history, and has a reputation for its distinctive style, quality construction, and award-winning customer experience. The Company is an industry leader in energy-efficient homebuilding, an eleven-time recipient of the U.S. Environmental Protection Agency's (EPA) ENERGY STAR® Partner of the Year for Sustained Excellence Award and Residential New Construction Market Leader Award, as well as a four-time recipient of the EPA's Indoor airPLUS Leader Award.
For more information, visit www.meritagehomes.com.
About Operation Homefront: Operation Homefront is a national nonprofit organization whose mission is to build strong, stable, and secure military families so that they can thrive – not simply struggle to get by – in the communities they have worked so hard to protect. Recognized for superior performance by leading independent charity oversight groups, 83 percent of Operation Homefront expenditures go directly to programs that support tens of thousands of military families each year. Operation Homefront provides critical financial assistance, transitional and permanent housing, and family support services to prevent short-term needs from turning into chronic, long-term struggles. Thanks to the generosity of our donors and the support from thousands of volunteers, Operation Homefront proudly serves America's military families. For more information, visit OperationHomefront.org.
Contact:Emily Tadano, VP Investor Relations and External Communications (480) 515-8979 media@meritagehomes.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Karl-Anthony Towns trade proposal lands Knicks new star
The post Karl-Anthony Towns trade proposal lands Knicks new star appeared first on ClutchPoints. The Eastern Conference is already viewed as much weaker and more talent-depleted than the Western Conference. It could look a whole lot different after the upcoming offseason, too. The Milwaukee Bucks' Giannis Antetokounmpo has already signaled that he is open to being traded. While it wasn't a formal trade request, his days in Milwaukee are likely numbered, especially because Damian Lillard tore his achilles tendon. Karl-Anthony Towns is another superstar who could be moved. Advertisement The New York Knicks traded for the center last offseason. While it is unlikely that he'd be moved again just one year later, especially because the Knicks played in the Eastern Conference Finals, some believe that he could be traded this offseason. Kevin O'Connor is one expert who has advocated for Towns to be traded again. Blockbuster deals are commonplace in the modern NBA, so perhaps Antetokounmpo could be traded for Towns. Giannis Antetokounmpo for Karl-Anthony Towns trade proposal Brad Penner-Imagn Images Knicks receive: Giannis Antetokounmpo Bucks receive: Karl-Anthony Towns, Ariel Hukporti Antetokounmpo is not only one of the best players in the NBA, but the two-time MVP is arguably the best player in Bucks history. The Bucks will be hesitant to trade him for that reason, but a franchise reset may be necessary. Most have predicted that Antetokounmpo would be traded to the Houston Rockets or San Antonio Spurs. Advertisement These are up-and-coming teams that are ready to take the next step forward, and they have tons of tradable assets, most notably in the form of an excess amount of draft capital. While a surplus of draft picks and young players could entice the Bucks, that kind of trade would lead to a rebuild, and the Bucks may want to avoid that. The alternative would be doing a superstar-for-superstar trade. Antetokounmpo and Towns have nearly identical contracts, so only Ariel Hukporti would need to be added in a deal to make the money work. Towns is only one year younger than Antetokounmpo, so he could come into Milwaukee and offer similar All-Star production, albeit in a completely different style of play. Towns is the best 3-point shooting center ever, whereas Antetokounmpo is a physical freak who thrives getting to the rim. Antetokounmpo has played more center in recent years, and Brook Lopez is an unrestricted free agent this offseason. The Bucks need somebody who can play heavy minutes at the five, and if they decide against a full-blown rebuild, then a deal for Towns could make sense. Would the Knicks trade Karl-Anthony Towns for Giannis Antetokounmpo? Knicks' head coach, Tom Thibodeau, has a very distinctive coaching style. He loves players who are elite on defense and play with intensity, and he is known to play his starters a lot of minutes. Because of that, Antetokounmpo would be a great fit for the team. Bailing on Towns this quickly after trading for him would be a little bizarre, but in a trade where they don't give up any other assets, the Knicks could view a Towns-for-Antetokounmpo swap as an upgrade. Advertisement The Greek Freak has a Defensive Player of the Year award to his name, whereas Towns was criticized during the Knicks playoff run for suspect defense. The Knicks are filled with lanky players who can guard inside or outside, such as Mikal Bridges and OG Anunoby, and Antetokounmpo would provide even more of that. In the Eastern Conference Finals, the Indiana Pacers thrived when Towns shared the floor with Jalen Brunson. If Antetokounmpo replaced Towns, though, the Knicks would have a star duo that would seemingly fit better together. The risk with this trade is that athleticism fades with age, and Antetokounmpo is more reliant on his physical attributes than a skilled player like Towns is. Even so, the Knicks are so close to getting back to the NBA Finals for the first time since 1999, and they could view Antetokounmpo as the player who could get them back to championship glory.
Business Upturn
an hour ago
- Business Upturn
U.S. FDA approves third indication of darolutamide for patients with advanced prostate cancer
U.S. FDA approves third indication of darolutamide for patients with advanced prostate cancer Darolutamide is the first and only in the U.S. and FDA-approved androgen receptor inhibitor (ARi) for the treatment of patients with hormone-sensitive prostate cancer (mHSPC), in combination with androgen deprivation therapy (ADT), with or without chemotherapy. This third approval is based on positive results from the pivotal Phase III ARANOTE trial and broadens the indication profile of darolutamide in mHSPC, enabling its use in combination with ADT, with or without chemotherapy (docetaxel). Darolutamide plus ADT reinforces the established safety and tolerability profile of darolutamide for prostate cancer patients across all approved indications. Orion's collaboration partner Bayer announced today that the U.S. Food and Drug Administration (FDA) has approved the oral androgen receptor inhibitor (ARi) darolutamide in combination with androgen deprivation therapy (ADT) for use in patients with metastatic castration-sensitive prostate cancer (mCSPC), which is also known as metastatic hormone-sensitive prostate cancer (mHSPC). The approval is based on positive results from the pivotal Phase III ARANOTE trial, which showed that darolutamide plus ADT significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT (HR 0.54; 95% CI 0.41–0.71; P<0.0001) in patients with mHSPC. With this approval, darolutamide plus ADT is indicated in the U.S. for the treatment of adult patients with mHSPC either with or without docetaxel. In addition, darolutamide is approved for the treatment of adult patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease. Prostate cancer is the second most common cancer in men and the fifth most common cause of cancer death in men worldwide.1 In 2022, an estimated 1.5 million men were diagnosed with prostate cancer, and about 397,000 died from the disease worldwide.1 Prostate cancer diagnoses are projected to increase to 2.9 million by 2040.2 Darolutamide, under the brand name Nubeqa®, is already approved in mHSPC in combination with ADT and docetaxel in over 85 markets around the world. It's also approved in combination with ADT for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease in more than 85 countries around the world. An approval process in the EU for the treatment of mHSPC in combination with ADT (without docetaxel) is already underway by Bayer. Nubeqa achieved blockbuster status in September 2024, with annual sales reported by Bayer reaching EUR 1.52 billion for the full year of 2024. Darolutamide is developed jointly by Orion and Bayer. About the ARANOTE trial The ARANOTE trial is a randomized, double-blind, placebo-controlled Phase III study designed to assess the efficacy and safety of darolutamide plus ADT in patients with mHSPC. 669 patients were randomized 2:1 to receive 600 mg of darolutamide twice daily or matching placebo in addition to ADT. The primary endpoint of this study is rPFS, measured as time from randomization to date of first documented radiological progressive disease or death due to any cause, whichever occurs first. Secondary endpoints include overall survival (time to death from any cause), time to first castration resistant event, time to initiation of subsequent anti-cancer therapy, time to prostate-specific antigen (PSA) progression, PSA undetectable rates, time to pain progression, and safety assessments. Results from the Phase III ARANOTE trial presented at ESMO 2024 and published in The Journal of Clinical Oncology showed that darolutamide plus ADT significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT (HR 0.54; 95% CI 0.41–0.71; P<0.0001), in patients with mHSPC. Consistent benefits in radiological progression-free survival (rPFS) were observed across prespecified subgroups, including patients with high-volume (HR 0.60, 95% CI: 0.44-0.80) and low-volume (HR 0.30, 95% CI: 0.15-0.60) mHSPC. The incidence of adverse events in the treatment group with darolutamide plus ADT in the ARANOTE study was comparable to placebo plus ADT. Darolutamide plus ADT was generally well tolerated and showed lower discontinuation rates due to adverse events compared to placebo plus ADT. About darolutamide Darolutamide is an oral ARi with a unique chemical structure that binds with high affinity to the androgen receptor and exhibits a strong antagonistic effect against the androgen receptor inhibiting the receptor function and the growth of prostate cancer cells. Additionally, preclinical models and neuroimaging data in healthy humans support darolutamide's low potential for blood-brain barrier penetration. Darolutamide (plus ADT or plus ADT and docetaxel) demonstrated a side effect profile in both registrational studies in mHSPC where the incidences of adverse events were roughly similar to the respective comparator arm. Darolutamide is a treatment option for doctors and patients, considering its tolerability and low risk of drug interaction. A robust clinical development program is underway investigating darolutamide across various stages of prostate cancer. The program includes the Phase III ARASTEP trial evaluating darolutamide plus ADT compared to ADT alone in hormone-sensitive high-risk biochemical recurrence (BCR) prostate cancer, who have no evidence of metastatic disease by conventional imaging and a positive PSMA PET/CT at baseline. Furthermore, darolutamide is also being investigated by Bayer in the collaborative Phase III DASL-HiCaP (ANZUP1801) trial led by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). The study evaluates darolutamide as an adjuvant treatment for localized prostate cancer with very high risk of recurrence. About metastatic hormone-sensitive prostate cancer At the time of diagnosis, most men have localized prostate cancer, meaning their cancer is confined to the prostate gland and can be treated with curative surgery or radiotherapy. mHSPC is a stage in the disease where the cancer has spread outside of the prostate to other parts of the body. Up to 10% of men will present with mHSPC when first diagnosed.3,4,5 For patients with mHSPC, ADT is the cornerstone of treatment, in combination with chemotherapy docetaxel and/or an androgen receptor inhibitor (ARi). Despite treatment, most men with mHSPC will eventually progress to castration-resistant prostate cancer (CRPC), a condition with limited survival. Contact person: Tuukka Hirvonen, Investor Relations tel. +358 10 426 2721 References Bray F et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Accessed: September 2024. James ND et al. Lancet 2024; 403: 1683–722. Piombino C et al. Cancers (Basel). 2023 Oct 11;15(20):4945. Helgstrand JT et al. Cancer. 2018;124(14):2931-2938. Buzzoni C et al. Eur. Urol. 2015;68:885–890. Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Finland Orion is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. In 2024 Orion's net sales amounted to EUR 1,542 million and the company employed about 3,700 professionals worldwide, dedicated to building well-being. Orion's A and B shares are listed on Nasdaq Helsinki. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Yahoo
an hour ago
- Yahoo
Pete Alonso, Juan Soto, and Francisco Lindor on big games at the plate after Mets win
So-So Juan Soto: Expectations, Media Scrutiny, and Will He Bounce Back? Is Juan Soto living up to his massive $765M contract with the New York Mets? In this episode of Big League Buzz, hosts Scott Gulbransen and Evan Groat dive into Soto's underwhelming 2025 season, exploring whether performance, pressure, or sky-high expectations are causing the slump. From his decreased bat speed to the intense New York media scrutiny, we break it all down. Plus, we discuss Soto's move from the Yankees, family influence on his decision, and if he'll hit .300 by the All-Star break. Don't miss this deep dive into one of baseball's biggest stories! - Subscribe for more MLB insights! - Visit us at for exclusive baseball coverage! - Check out Evan's interview with Andy McCullough on The Sportsnaut Interview podcast: Timestamps: 0:00 - Intro to Big League Buzz 1:02 - Juan Soto's Mets Struggles Begin 4:00 - Tony Gwynn vs. Elly De La Cruz: Crazy Strikeout Stat 7:00 - Soto's $765M Contract: Pressure or Performance? 12:01 - Yankee Fans Boo Soto: Emotional Impact 19:21 - Family Influence on Soto's Mets Decision 22:02 - New York Media Scrutiny: Is It Too Much? 26:58 - Will Soto Hit .300 by the All-Star Break? 29:50 - Evan's Upcoming Interview with Andy McCullough 33:00 - Outro & Memorial Day Baseball Preview 33:35 Now Playing Paused Ad Playing
